First American Bank Acquires New Stake in DexCom, Inc. (NASDAQ:DXCM)

First American Bank acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 26,263 shares of the medical device company’s stock, valued at approximately $2,042,000.

Several other hedge funds also recently made changes to their positions in DXCM. Versant Capital Management Inc purchased a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Heck Capital Advisors LLC acquired a new stake in DexCom in the fourth quarter valued at $38,000. Midwest Capital Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter worth $54,000. RPg Family Wealth Advisory LLC acquired a new position in shares of DexCom during the 3rd quarter worth $57,000. Finally, Rothschild Investment LLC lifted its stake in shares of DexCom by 250.5% in the fourth quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock valued at $58,000 after purchasing an additional 536 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 2.3 %

Shares of NASDAQ DXCM opened at $87.81 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock’s 50-day simple moving average is $84.53 and its 200-day simple moving average is $76.55. The firm has a market cap of $34.31 billion, a price-to-earnings ratio of 61.41, a PEG ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,083 shares of company stock valued at $3,309,794. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DXCM. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group upped their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Wells Fargo & Company boosted their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.